The analyse of effectiveness in HBeAg-positive chronic viral hepatitis B treated by adefovir dipivoxil combined with bicyclol
10.3760/cma.j.issn.1003-9279.2009.04.019
- VernacularTitle:阿德福韦酯联合双环醇片治疗HBeAg(+)慢性乙型肝炎疗效分析
- Author:
Dai-Rong XIANG
1
;
Ji-Fang SHENG
Author Information
1. 浙江大学医学院附属第一医院
- Keywords:
Hepatitis B;
chronic;
Adefovir dipivoxil;
Bieyclo compounds
- From:
Chinese Journal of Experimental and Clinical Virology
2009;23(4):299-301
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the efficacy of adefovir dipivoxil combined with bieyclol in treatment of HBeAg-positive chronic viral hepatitis B (CHB). Methods A total ofgl patients with CHB were randomized into experimental group and control group to be treated. The patients in experimental group (46 samples) received adefovir dipivoxil orally 10 nag daily and bieyclol orally 150 mg daily for 48 weeks and those in control group (45 samples) received adefovir dipivoxil orally 10 mg daily alone for 48 weeks. The serum aminotransferace (ALT/ AST), HBV-DNA, HBeAg/antiHBe were observed before and after treatment. Results Compared with pre-treatment, the serum aminotransferace were all decreased obviously in two groups, the experimental group is better (P <0.05). HBVDNA negative conversion rate was significantly higher in experimental group than in the control group(47.8% vs. 31.1%, P < 0.05). There were nostatistically differrence between the two groups in the portion of HBeAg loss rate and HBeAg seroeonversion rate. There were no obvious adverse reaction in the study. Conclusion Adefovir dipivoxil combined with bicyclol is efective in the treatment of chronic hepatitis B.
